Hooper Holmes Files 2016 Annual Report on Form 10-K and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
67
Hooper Holmes Files 2016 Annual Report on Form 10-K and Form S-4 Regarding Proposed Merger with Provant Health Solutions

— Affirms Outlook Following Merger Announcement

— Executing Well for Long-Term Growth

OLATHE, Kan., March 20, 2017 (GLOBE NEWSWIRE) -- Hooper Holmes Inc. (NYSE: HH ) has filed its Annual Report on Form 10-K for the year ended December 31, 2016, and Form S-4 related to the Company's proposed merger with Provant Health Solutions LLC, with the Securities and Exchange Commission (“SEC”).

As reported in the Company's Annual Report, Hooper’s adjusted EBITDA for the 2016 fourth quarter improved by 65% compared to the same period in 2015. For the full year 2016, the Company’s adjusted EBITDA was negative $3.1 million, reflecting an improvement of $1.2 million, or 28% from the prior year. 

"We believe continued improvements in our adjusted EBITDA demonstrate the benefits of driving to scale, which we anticipate will accelerate upon completion of our merger with Provant. Further, our clients have reacted positively to the merger announcement. We are enthusiastic about our prospects as a combined company, with scale, growth and synergies expected to significantly improve operating cash flow," said Henry E. Dubois, President and CEO of Hooper Holmes.

On March 8, 2017, the Company announced an agreement to combine with Provant Health Solutions LLC in an all-stock transaction which will create one of the largest, pure-play health and wellness companies in the United States.   

Since announcing the pending merger with Provant, Hooper Holmes has filed a Form S-4 proxy statement for review by the SEC in preparation for a special shareholders' meeting to approve the merger. In this filing, the Company reported that, on a pro-forma basis as if combined, 2016 revenues for the two companies were $67 million, net of gift-card pass-through revenue.

Once the Form S-4 has been reviewed by the SEC and becomes effective, the Company anticipates closing the merger at the end of April or in early May 2017, pursuant to the approval of Hooper Holmes’ shareholders.

Financing to support the merger transaction and provide working capital has been arranged from SWK Holdings, a specialized finance company focused on the healthcare sector, through a $6.5 million, five-year term loan at LIBOR plus 12.5%, a reduction of 150 basis points from Hooper's current term facility. The Company has also expanded its current asset-based credit facility from $7 million to $10 million with an accordion to $15 million during high-volume months. Both of Hooper’s current lenders are participating in this transaction and are providing sufficient working capital to support integration and growth.

The Company’s audit opinion in the Form 10-K for the year ended December 31, 2016, included a going concern clarifying statement as it did in 2015. The Company will continue to monitor its liquidity carefully and work to reduce this uncertainty.

Copies of the Annual Report on Form 10-K and the Form S-4 are available to be viewed or downloaded at www.hooperholmes.com/investors .

About Hooper Holmes

Hooper Holmes mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, employers and brokers, government organizations and academic institutions nationwide. Under the Accountable Health Solutions brand, the Company combines smart technology, healthcare and behavior change expertise to offer comprehensive health and wellness programs that improve health, increase efficiencies and reduce healthcare delivery costs.  www.hooperholmes.com

About Provant

Provant is a leader of comprehensive workplace well-being solutions in North America, with a growing global presence. Founded in 2001, Provant partners with employers to improve employee health and productivity while supporting healthcare cost management. Through a network of 13,000+ health professionals, Provant touches millions of lives by delivering customized well-being strategies and services on-site, telephonically and digitally utilizing advanced data management. Provant is a privately held company headquartered in East Greenwich, Rhode Island.  www.provanthealth.com

Additional Information about the Proposed Merger and Where to Find It In connection with the previously disclosed proposed merger with Provant, the Company has filed a registration statement on Form S-4 with the Securities and Exchange Commission (the “SEC”), including a proxy statement/prospectus, but the registration statement has not yet become effective. Shareholders of the Company are urged to read these materials because they contain important information about the Company, Provant, and the proposed merger. The proxy statement/prospectus and other documents filed by the Company with the SEC may be obtained free of charge at the SEC web site at www.sec.gov . In addition, investors and security holders may obtain free copies of the documents filed with the SEC by the Company by directing a written request to: Hooper Holmes, Inc., 560 N. Rogers Road, Olathe, Kansas 66062, Attention: Legal Department. Shareholders of the Company are urged to read the proxy statement/prospectus and the other relevant materials before making any voting or investment decision with respect to the proposed merger.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

The Company and its directors and executive officers and Provant and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of the Company in connection with the proposed merger. Information regarding the special interests of these directors and executive officers in the merger is included in the proxy statement/prospectus referred to above. Additional information regarding the directors and executive officers of the Company is also included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, which is available free of charge at the SEC web site (www.sec.gov) and from the Company at the address described above.

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intends," "plan," and "will" or, in each case, their negative, and other variations or comparable terminology. These forward-looking statements include all statements other than historical facts. Any forward-looking statement made by management during this call is not a guarantee of future performance, and actual results may differ materially from those expressed in or suggested by the forward-looking statements, as a result of various factors, including, without limitation the factors discussed in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2016, as the same may be updated from time-to-time in subsequent filings with the Securities and Exchange Commission. Any forward-looking statement made by management on this call speaks only as of the date hereof, and the Company has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. In addition, management uses the non-GAAP performance measures EBITDA and Adjusted EBITDA in this press release. 

For further information: Hooper Holmes Henry E. Dubois President and CEO (913) 764-1045 Investors: Andrew Berger S.M. Berger & Company (216) 464-6400 Investors: Scott Gordon CORE IR (516) 222-2560

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 234

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 178

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Photocure Navigates AssureMDx's Medicare Journey

Updated Category News Views 70

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

Continue Reading
Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 115

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
Strathcona Resources Q3 2026: Dividends, Deals, and Growth

Updated Category News Views 202

Digging into Strathcona's Third Quarter Strathcona Resources (TSX: SCR) is strutting its stuff again, dropping a third-quarter report that reads like a playbook for solid energy sector performance. First off, let’s talk about that dividend bump. The company decided to sprinkle some cheer with a 7% increase in its quarterly dividend, now at $0.32 per share. Not exactly...

Continue Reading
Telespazio & Rivada Forge Secure Satellite Network

Updated Category News Views 0

Rivada's Outernet: A New Era of Connectivity Forget the terrestrial wires; we're talking about 600 satellites playing a space-age game of telephone. That's Rivada's Outernet for you, an orbital mesh network that's about to upend the very nature of global communications. Telespazio's new partnership with Rivada is like strapping a rocket onto secure connectivity in the...

Continue Reading
Korean 'Glocal' Districts Entice U.S. Tourists with Local Flavor

Updated Category News Views 97

Gwangju's Dongmyeong-dong is like the neighborhood artists and hipsters flock to in New York—except it’s got a Korean twist. Nestled in the Jeonnam region, this place is hot on American tourists' radar for its spicy mix of local culture, unique eats, and shops that scream individuality. It's becoming a magnet for folks who want to get a taste of Korean life but with a...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
SpaceMap Tackles Space Traffic With AI Innovation

Updated Category News Views 0

SpaceMap Takes Aim at the Crowded Space Above You ever look up and wonder what's hurtling above our noggins? More satellites than you can shake a stick at, that's what. And don't even start me on the debris floating around. This ain't just rocket science anymore; it's a crowded dance floor, and someone's gotta manage it. Enter SpaceMap, a plucky South Korean startup that...

Continue Reading
UAE Pioneers eATA Carnet System Beyond Europe

Updated Category News Views 56

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Postpones Asia Cruise Ship Launch Amid Challenges

Updated Category News Views 232

Disney Delays Launch of Its First Asia Cruise Ship Walt Disney Co. (NYSE: DIS) has announced a three-month delay in the inaugural voyage of its first Asia-based cruise ship, the Disney Adventure. Originally set to embark from Singapore on December 15, the new launch date is now March 10, 2026, due to unexpected setbacks in the shipbuilding process. Challenges in...

Continue Reading
Promising Outcomes from ASPIRO Phase 1/2a Trial for Parkinson's

Updated Category News Views 159

Promising Results from Aspen Neuroscience's Clinical Study Aspen Neuroscience has recently shared encouraging insights from the ASPIRO Phase 1/2a clinical trial, focusing on their innovative cell therapy, ANPD001, aimed at treating Parkinson's Disease. This investigational approach leverages autologous dopaminergic neuronal precursor cells (DANPC) that hold the potential...

Continue Reading
Exploring Honeywell Intl's Options Trends and Market Analysis

Updated Category News Views 213

Understanding Honeywell Intl's Current Options Landscape The dynamic environment of finance recently showcased an intriguing shift with notable bearish movements concerning Honeywell Intl. The latest analysis of options trading data for Honeywell Intl (HON) has spotlighted a total of 10 unique trades that have piqued interest among traders. In an examination of the...

Continue Reading
Transforming Business with Google Agentspace and Premier Cloud

Updated Category News Views 217

Transforming Business with Google Agentspace and Premier Cloud Premier Cloud has been recognized as a launch partner for Google Agentspace, Google's innovative new AI platform that aims to revolutionize enterprise search and productivity. This partnership is a significant milestone for Premier Cloud, a prominent Google Cloud Premier Partner, renowned for its expertise in...

Continue Reading
Transforming Biotechnology: A New Era for Advanced Therapies

Updated Category News Views 156

Innovative Biomanufacturing Comes to Saudi Arabia At the forefront of a new biotechnology initiative, a strategic partnership has emerged between King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Laboratories, LLC, unveiling a state-of-the-art Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus. This exciting development represents a...

Continue Reading